A supplemental New Drug Application (sNDA) for Pfizer’s Talzenna (talazoparib) in combination with Xtandi (enzalutamide) has been accepted for Priority Review by the US FDA. The application is to ...
Takeda has announced new data from the two pivotal phase 3 studies of zasocitinib (TAK-279) in adults with moderate-to-severe ...
Almirall’s submission to extend its Marketing Authorisation Application (MAA) for Ebglyss (lebrikizumab) to treat moderate-to ...
Chapple has held senior leadership roles at DontBePatient Intelligence, Alira Health, Innovative Trials, Cognizant and ICON ...
How do we translate individual experiences into support that helps others and create support that feels personal but remains ...
Independent network The Bloc has appointed Jon Chapman as European Executive Creative Director. Chapman previously held ...
Veradermics has announced positive topline results from its open-label phase 2 clinical trial (Study ‘207’) evaluating ...
Camena Bioscience, a pioneer in enzymatic DNA synthesis producing complex, high-fidelity gene constructs for AI-driven ...
AstraZeneca has entered into an exclusive licence agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel ...
Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each ...
The unique combination of technology marks 25 years of industry innovation and expertise, and signals company’s next phase of ...
The phrase "patient-centered care" is tossed around freely in healthcare corporate boardrooms. Yet, for more than half the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results